Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Altrius Capital Management Inc

Altrius Capital Management Inc lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.4% during the second quarter, Holdings Channel reports. The fund owned 46,134 shares of the biopharmaceutical company’s stock after acquiring an additional 200 shares during the period. Altrius Capital Management Inc’s holdings in Gilead Sciences were worth $3,556,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Bank Julius Baer & Co. Ltd Zurich raised its position in shares of Gilead Sciences by 98,797.6% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 394,005,889 shares of the biopharmaceutical company’s stock worth $30,366,034,000 after acquiring an additional 393,607,491 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Gilead Sciences by 324.8% in the first quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock valued at $1,070,232,000 after buying an additional 13,764,169 shares during the last quarter. Norges Bank acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $1,115,186,000. Moneta Group Investment Advisors LLC grew its position in Gilead Sciences by 96,759.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 10,111,194 shares of the biopharmaceutical company’s stock valued at $868,046,000 after buying an additional 10,100,755 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Gilead Sciences by 70.6% during the first quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock worth $921,006,000 after acquiring an additional 6,410,047 shares during the period. Hedge funds and other institutional investors own 82.33% of the company’s stock.

Gilead Sciences Stock Up 0.3 %

Shares of GILD stock traded up $0.19 during trading on Monday, hitting $75.64. 1,663,640 shares of the company were exchanged, compared to its average volume of 5,752,461. Gilead Sciences, Inc. has a twelve month low of $72.87 and a twelve month high of $89.74. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.20 and a current ratio of 1.34. The firm has a market capitalization of $94.25 billion, a price-to-earnings ratio of 16.27, a P/E/G ratio of 1.00 and a beta of 0.32. The business’s 50-day simple moving average is $76.82 and its 200 day simple moving average is $77.26.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.38. Gilead Sciences had a return on equity of 39.30% and a net margin of 21.45%. The firm had revenue of $7.05 billion for the quarter, compared to the consensus estimate of $6.81 billion. During the same quarter in the previous year, the company posted $1.90 earnings per share. The business’s quarterly revenue was up .1% compared to the same quarter last year. As a group, analysts forecast that Gilead Sciences, Inc. will post 6.76 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be paid a dividend of $0.75 per share. The ex-dividend date is Thursday, December 14th. This represents a $3.00 annualized dividend and a yield of 3.97%. Gilead Sciences’s payout ratio is 64.38%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on GILD. StockNews.com assumed coverage on Gilead Sciences in a research note on Thursday, October 5th. They issued a “strong-buy” rating for the company. Piper Sandler reduced their price objective on Gilead Sciences from $105.00 to $100.00 and set an “overweight” rating on the stock in a research note on Monday, July 24th. Royal Bank of Canada reduced their price objective on Gilead Sciences from $78.00 to $77.00 and set a “sector perform” rating on the stock in a research note on Tuesday, November 14th. Deutsche Bank Aktiengesellschaft started coverage on shares of Gilead Sciences in a research note on Thursday, November 9th. They issued a “hold” rating and a $75.00 target price for the company. Finally, Leerink Partnrs restated a “market perform” rating on shares of Gilead Sciences in a report on Wednesday, October 11th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $88.22.

Insiders Place Their Bets

In related news, insider Merdad Parsey sold 1,501 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total transaction of $115,561.99. Following the completion of the transaction, the insider now directly owns 70,130 shares in the company, valued at approximately $5,399,308.70. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Gilead Sciences news, insider Merdad Parsey sold 1,501 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total value of $115,561.99. Following the transaction, the insider now directly owns 70,130 shares in the company, valued at $5,399,308.70. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 17th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the transaction, the chief financial officer now directly owns 104,003 shares in the company, valued at $8,320,240. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.